Phase Ia single ascending dose controlled trial of AEM 28 in patients with elevated cholesterol levels.
Phase of Trial: Phase I
Latest Information Update: 02 Sep 2014
At a glance
- Drugs AEM 28 (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions; First in man
- Sponsors Capstone Therapeutics; LipimetiX
- 02 Sep 2014 Status changed from `recruiting' to `completed', as reported by a Capstone Therapeutics media release.
- 02 Sep 2014 Interim results published in a Capstone Therapeutics media release.
- 09 Apr 2014 Dosing has been initiated, according to a media release from LipimetiX and Capstone Therapeutics.